We further identified RAC3 as a downstream target of METTL3, and RAC3 facilitates NSCLC cell migration via the AKT/NF-κB pathway, suggesting that RAC3 m6A modification may serve as a potential therapeutic target for lung cancer treatment (Figure 8K). This evidence concerns the gene NFKB1 and lung carcinoma.